by Gonzalo Payan | Feb 3, 2023
MAX BioPharma reports on the inhibition of profibrotic signaling in cellular models of lung and kidney fibrosis by its oxysterol drug candidate, Oxy210, an orally available small molecule. Please follow the link for a copy of the manuscript....by Gonzalo Payan | May 18, 2022
MAX BioPharma reports on the anti-inflammatory effects of its oxysterol drug candidate, Oxy210, an orally available small moleculedifferent from steroids and NSAIDs. Please follow the link for a copy of the manuscript....by Gonzalo Payan | Sep 1, 2021
MAX BioPharma is pleased to announce that it has been awarded an SBIR Direct-to-Phase II grant from the NIH (NIAMS) titled: “Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion” (R44AR079335-01). With limited options on the market, the medical...by Gonzalo Payan | Sep 1, 2021
MAX BioPharma scientists, along with its UCLA colleagues, publish new paper titled “Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice” as they progress their fibrotic disorders program...by Gonzalo Payan | Feb 2, 2021
In collaboration with scientists at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan, MAX BioPharma scientists have identified new substances with antiviral activity against the novel coronavirus, SARS-CoV-2, the virus that caused the ongoing...